The Epstein-Barr virus (EBV) nuclear antigen 2 (EBNA2) is one of the first EBV-encoded gene products expressed after infection of primary B lymphocytes. EBNA2 is essential for the growth-transforming potential of the virus and it functions as a transcriptional activator of a set of viral and cellular genes. Sequencespecific DNA-binding by EBNA2 has not been demonstrated but the molecule is targeted to specific DNA regions by a cellular protein, RBP-JK, which recognizes the GTGGGAA sequence present in the regulatory region of all EBNA2-responsive promoters defined so far. We have determined the contribution of a RBP-Jx recognition sequence, an adjacent interferon-stimulated response element (ISRE) motif and a PU.l-binding site in the LMP1 regulatory sequence (LRS) to EBNA2-induced transactivation of the promoter by sitedirected mutagenesis of LRS-carrying reporter plasmids. EBNA2 responsiveness was reduced by approximately twofold when either or both of the RBP-JK-binding and ISRE sequences were mutated. ISRE seemed to function as an EBNA2-independent positive element. On the other hand, mutation of the PU box resulted in a drastic reduction of EBNA2 responsiveness, irrespective of whether the RBP-JK site or the ISRE motif was present. A comparative study by deletion mutation identified regions of EBV B95-8 EBNA2 involved in the transactivation of the LMP1 and the EBNA Cp promoters. Two domains of EBNA2 defined by deletion of amino acids 247-337 and 437-476 were found to be important for the activation of both promoters, while two different domains corresponding to residues 4-18 and 118-198 were required solely for the LMP1 promoter. Thus, EBNA2 must activate the LMP1 and Cp promoters by different mechanisms. All deletions involved in transcriptional activation of the two promoters contained regions that are conserved in EBNA2 of B95-8 EBV (type 1), AG876 EBV (type 2) and herpesvirus papio origin.
Introduction
The EpsteimBarr virus (EBV), a widespread human herpesvirus, is the aetiological agent of infectious mononucleosis and is also associated with several human malignancies, including Burkitt's lymphoma (BL) and nasopharyngeal carcinoma (Henle & Henle, 1966; Herbst et al., 1991; Young et al., 1989) . Infection of B lymphocytes in vitro by EBV is generally followed by deregulation of cell proliferation and persistence of the virus in a latent state, where the virus genome is maintained in multiple copies as autonomously replicating circular episomes. In such lymphoblastoid cell lines only 11 of more than 80 known EBV genes are expressed, suggesting that the genes responsible for two allelic forms, one in EBV type A or EBV-1 (found in B95-8 and M-ABA strains of the virus) and one in EBV type B or EBV-2 (found in the Jijoye and AG876 strains). The type A alleles of EBNA2 transform B lymphocytes more efficiently and transactivate the expression of CD23 to a higher level . Since a secreted cleavage product of CD23 has been shown to act as an autocrine B cell growth factor (Swendeman & Thorley-Lawson, 1987) , these data are consistent with the discrepancy between the two EBV types' transforming potential. Deletion analysis and sitedirected mutagenesis of the EBNA2A protein from the type 1 strain W91 have identified four regions which are essential for transformation and for transactivation of the LMP1 promoter . Region one is amino acids 19 to 110, which consists mostly of a polyproline repeat. The second region was identified by a linker insertion between Trp 32° and Pro ~1 in the EBNA2 protein. This part of EBNA2 has now been shown to mediate the interaction with a 63 kDa cellular protein, RBP-JK (Ling et al., 1993 a) . The RBP-Jx nucleic acid-binding motif was originally identified by virtue of its ability to confer EBNA2 inducibility to the Cp, CD23 and LMP2A promoters (Ling et al., 1994; Zimber-Strobl et al., 1994) . EBNA2 amino acids 310 to 336 are sufficient for RBP-Jx interaction and a short sequence PPWWPP (amino acids 317-322) conserved between type 1 and type 2 EBNA2 probably mediates this interaction . Region three is amino acids 333 to 425, a segment which includes an Arg-Gly repeat at amino acids 337 to 354. Recently, however, Tong et al. (1994) showed that an EBNA2 construct that carries a deletion of this part of EBNA2 still activated the LMP1 gene but did not induce transformation. The fourth region is amino acids 426 to 472, which includes a core acidic transactivation domain, amino acids 449 to 462 . This core acidic domain of EBNA2 can be replaced by the analogous domain of the prototype acidic transactivator, herpes simplex virus VP16, without loss of transforming activity, indicating that EBNA2 and VP16 acidic domains are functionally similar (Cohen, 1992) .
The aim of this study was to analyse the importance of specific EBNA2 regions for the transactivation of the EBNA Cp and LMP1 promoters and to evaluate the relative contribution to EBNA2-induced promoter activation of three transcriptional elements present in the LMP 1 regulatory region: an ISRE (interferon-stimulated response element) consensus motif, an RBP-J~c recognition sequence and a PU. 1-binding site. We have defined four EBNA2 domains with a distinct influence on the ability of the protein to transactivate the LMP1 promoter. Two did not seem to be critical for the transactivation of the Cp promoter. The data suggest that EBNA2 interacts differently with the LMP1 and Cp promoters since different domains of the protein participate in the transactivation processes. Furthermore, results obtained with site-directed mutagenesis and DNase footprint analysis strengthened our previous conclusion that the RBP-JK site-containing LRS sequence is not essential for LMP1 promoter induction (F~hraeus et al., 1990, 1993) .
Methods
Plasmid construction. The EBNA2 expression vectors, pEAA6 and pSVEAA6, have been described previously (Ricksten et al., 1987; Ffihraeus et al., 1993) . The pSVEAA6 plasmid was further modified by converting the HindlII site in the bacterially derived part of the vector to a Sail site, resulting in pSVEAA6(Sa/I). For the construction of deletion mutants of EBNA2 a HindlII-BgllI fragment of pSVEAA6(Sa/I) containing the EBNA2-encoding sequence (position 48039 50628) was cloned into the pIBI31 vector (International Biotechnologies). This plasmid was used to create Bgill linker insertions in the EBNA2 gene using different restriction enzymes (Everett, 1987) . The EBNA2-containing HindIII-EcoRI fragment with the inserted linker from different mutated plasmids was then cloned back into pSVEAA6(Sa/I). The resulting EBNA2 expression vectors were cleaved with BgilI, which created two fragments due to the presence of the BglII linker in the EBNA2 gene and a BglII site in the vector. The two fragments obtained from each plasmid, which both carried parts of the EBNA2 gene, were isolated, ligated with EBNA2 fragments from other cleavages in appropriate combinations and cloned. Sequences corresponding to the following amino acids were deleted: 4-18 (deletion 1), 19-59 (2), 58-115 (3), 118-198 (4), 198-247 (5) , 247-337 (6), 337-388 (7), 388-436 (8) and 437-476 (9) . All constructs were verified by dideoxynucleotide chain termination sequencing utilizing the Sequenase system (USB).
The EBNA Cp reporter plasmids have been described . The BCR2 transcription initiation site at position 11336 of strain B95-8 EBV DNA is numbered as + 1. We have changed the names of the plasmids: pbAC2CAT is now pCp(-248)CAT and pbAC3CAT is now pCp(-1024)CAT (numbers within parenthesis indicate the 5' end of the EBV DNA inserts, which both have the same 3' end corresponding to position + 76).
The LMP1 regulatory sequence (LRS) is defined as nucleotides 169477 to 170151 of B95-8 EBV DNA, which corresponds to positions -634 to +40 relative to the transcription initiation site. The construct pgLRS(-634)CAT has been described (F~hraeus et aL, 1993) . The pgLRS (-198) CAT plasmid was kindly provided by Dr Sonia Lain (G6teborg University, Gothenburg, Sweden). The pgLRS(-259)CAT plasmid was made by cloning double-stranded synthetic oligonucleotides corresponding to the -259 to -215 region of LRS 5' of the EBV DNA sequence in the pgLRS(-217) CAT plasmid (Sj6blom et al., 1995) . A series of mutated derivatives of pgLRS( -259)CAT was made using oligonucleotides with purine-pyrimidine transversions in the following positions: -241 to -219 (ml), -254 to -249 (m2), -241 to -219 and -254 to -249 (m3). The unmutated and mutated oligonucleotides were also cloned in front of the ml derivative of the pgLRS(-217)CAT plasmid, with a mutation in the -170 to -t56 part of LRS. This resulted in four different constructs: pgLRS-(-259)CAT(m4), pgLRS(-259)CAT(m5), pgLRS(-259)CAT(m6) and pgLRS(-259)CAT(m7). The pgLRS(-217)CAT(m2) plasmid was made by cloning sets of double-stranded synthetic oligonucleotides corresponding to the LRS region -217 to -74 (with transverse mutations in -214 to -136) and a HindlII-Xmal fragment of LRS
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containing the region -73 to + 40, between the HindIII and SalI sites of the pgCAT plasmid described earlier (Fgthraeus et al., 1993) .
Cell culture, DNA transfections and CAT assays. DG75 is an EBV genome-negative BL cell line (Ben-Bassat et al., 1977) . The IB4 cell line was derived by transforming human placental lymphocytes with the B95-8 EBV strain (King et al., 1980) . The lymphoid cells were maintained as suspension cultures in RPMI 1640 medium (Life Technologies) supplemented with 10 % fetal calf serum, penicillin and streptomycin. DG75 cells (5 x l0 s) were transfected with 10 gg DNA of the reporter construct to be tested and 800 fmol of pEAA6 or pSV2gpt plasmid DNA, using the DEAE-Dextran technique (Ricksten et al., 1988) . In the EBNA2 deletion experiments 500 fmol of the pSVEAA6 vector, the EBNA2 deletion mutants or the pSVESV2gpt vector were used. Cells were harvested after 48 h and aliquots of the cell lysates were assayed for CAT activity (Ricksten et al., 1988) .
DNase I protection analysis. Nuclear extracts were prepared as described (Dignam et al., 1983) . The protease inhibitors antipain (5 lag/ml), leupeptin (5 lag/ml) and aprotinin (2 lag/ml) were added to the buffer in the final homogenization and dialysis steps. Aliquots were frozen in liquid nitrogen and stored at -70 °C. DNase I footprinting analysis utilized a DNA fragment corresponding to the -324 to -54 region of LRS. The probe was labelled by a repair reaction and purified from free isotope as described (Sj6blom et al., 1995) . Binding reactions (50 lal) contained 10 mM-Tris HC1 pH 7.5, 50 mM-NaCI, 1 mM-DTT, 1 mM-EDTA, 5 % glycerol, 1 lag poly(dI-dC), 6 fmol of 32P-labelled DNA (approximately 70000 c.p.m.) and the amount of nuclear proteins ranged from 60 to 100 tag (always added last). After incubation on ice for 25 rain, MgC12 and DNase I were added to a concentration of 4 mM and 300 ng/ml, respectively, and the incubation on ice was continued for 1 rain. DNase cleavage was stopped by the addition of EDTA to 5.3raM, followed by phenol-chloroform extraction and ethanol precipitation. The samples were then denatured and separated by electrophoresis in 6 % polyacrylamide gels (19: 1) in 8 M-urea (Ricksten et al., 1988) .
Results and Discussion

DNase I protection analysis
We and others have demonstrated that the regulatory region of the LMP1 EBV gene contains cis-acting elements that mediate the EBNA2-induced up-regulation of LMP1 expression (FAhraeus et al., 1990; Ghosh & Kieff, 1990) . To define further the LRS elements involved in interactions with transcription factors in B cells differing in EBNA2 expression, DNase footprinting experiments were performed. The footprint patterns using the coding strand of the -324 to -54 region and nuclear extracts of IB4 and DG75 cells ( Fig. 1) were largely similar but with some distinct differences. The DG75 and IB4 cell extracts both protected the -127/-119 LRS region from DNase I degradation (protection I; Fig. 1 ). The 3' portion of protection I was verified by performing DNase protection analysis of the complementary strand (data not shown). The region contains a sequence with a high degree of identity to a sis-inducible element (SIE). This element and the sisinducible factor (SIF) are components of a cellular signal transduction pathway which is activated by growth factors and regulates the transcription of certain genes (Sadowski et al., 1993) . SIE does not seem to play a major role, however, in the EBNA2-induced activation of the LMP1 promoter, at least not in the context of short LRS reporter constructs (Sj6blom et al., 1995) . The regions designated II, III and IV (Fig. 1) were also protected by both DG75 and IB4 cell extracts. However, we consistently observed a difference between the cell lines in that only a partial protection of region II (but not III and IV) was obtained with the IB4 cell extracts. Region II corresponds to the De domain defined by us, which was shown to be important for EBNA2 responsiveness of the LMP1 promoter (Sj6blom et al., 1995) and contains an octamer-homologous sequence. A POU domain protein was identified that bound to De and the addition of EBNA2 synthesized in vitro to DG75 cell extracts substantially reduced the formation of a complex between a De-containing oligonucleotide and the POU domain protein in electrophoretic mobility shift assays (EMSAs; Sj6blom et al., 1995) . Thus, both the DNase footprinting and the EMSA results suggest that EBNA2 directly or indirectly causes a destabilization of the complex formed by factors binding to the De region. Regions III and IV contain a purine-rich sequence that constitutes a recognition sequence for the PU. 1 and Spi-B transcription factors, a PU box. One or both of the factors seem to be essential for EBNA2 responsiveness (Laux et al., 1994; Johannsen et al., 1995; Sj6blom et al., 1995) .
The most distinct differences in the footprint patterns between EBV-negative DG75 cells and the EBV-positive, EBNA2-containing IB4 cell line were observed in the -257/-217 LRS region. DG75 cell extracts protected the -228/-217 (protection VI) and -257/-244 (protection VIII) regions, whereas IB4 cell extract protected the -234/-219 (protection VII) region. Protection VI most likely represents the binding of the RBP-JK factor in DG75 cells to the -223 to -217 part of LRS, which is known to contain a RBP-JK-binding site (Ling et al., 1993a; Laux et al., 1994; . In contrast, with IB4 cell extracts the corresponding protected segment (protection VII) was displaced somewhat further upstream to cover a binding site for the AML1 protein identified by Johannsen et al. (1995) . Thus, the footprint patterns seem to indicate that the binding of AML1 to LRS dominates over that of RBP-JK in IB4 cells. This is consistent with the observations that RBP-JK has a very low affinity for the RBP-JK-binding site in the context of the LMP1 promoter sequence (Ling et al., 1994) and that AML1 is expressed at high levels in EBV-positive cell lines . Alternatively, EBNA6 present in the IB4 nuclear extract may displace the RBP-Jtc factor (Robertson et al., 1995) .
Protection VIII contains a sequence homologous to an A. Sjdblom and others fection assay in DG75 cells (Fig. 2) . Mutation of the ISRE-homologous motif (-254 to -249) reduced the activity of the plasmids to the levels obtained with constructs in which both regions were mutated or deleted, suggesting that this element contributes to EBNA2 responsiveness. Mutation of a sequence that included the RBP-J~c-binding site had only a minor effect on EBNA2-induced promoter activity (Fig. 2) , although the EBNA2 responsiveness was reduced to about 50 % of the original level. This was caused by a small but significant (P < 0.001 in non-paired t-test) increase in promoter activity in the absence of EBNA2. It has been shown that RBP-JK can function as a transcriptional repressor (Dou et al., 1994) and that the effect of EBNA2 on RBP-J~c is to mask the repression by interacting with a specific domain of the protein (Hsieh & Hayward, 1995) . This might explain why the EBNA2-induced activity of the reporter plasmid is approximately the same whether the J~c site is present or not. When the contribution of the PU boxcontaining Dr region was investigated in a similar manner (Fig. 2) , all mutations of the potential PU. 1-binding site drastically reduced (but did not completely abrogate) the activity and inducibility of the reporter plasmids. This is in line with previous results showing that mutations of the PU.l-binding sequence have a profound effect on EBNA2 responsiveness (Sj6blom et al., 1993; Laux et al., 1994; Johannsen et al., 1995) .
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Domains of EBNA2A involved in the transactivation of the LMP1 and Cp promoters
To examine the role of different domains of EBNA2 in the transactivation of the LMP1 and the EBNA Cp promoters, nine plasmids containing deletion mutations throughout the EBNA2 gene, as indicated in Fig. 3 , were constructed. Each mutant induced the expression of EBNA2 polypeptides of the expected size and at approximately the same levels in transfected COS-1 cells and the polypeptides were appropriately transported to the nuclei of the transfected cells, as determined by immunoblotting and immunofluorescence analysis (data not shown). The ability of the EBNA2 mutants to transactivate the LMP1 promoter was assayed by cotransfection experiments in DG75 cells using two different LRS-CAT reporter plasmids: pgLRS(-634)CAT, which contains all LMP1 promoter regulatory elements defined so far and pgLRS (-198) CAT, which contains the PU box and the octamer-homologous site but lacks the RPB-Jlc site. In a series of transfections with the pgLRS(-634)CAT construct, four EBNA2 domains were identified that influenced the activating ability of the protein (Fig. 3 a,  b) . The transactivating function was completely lost when the negatively charged sequence between amino acids 436-477 (deletion 9) was deleted, and was reduced A. Sjgblom and others to about 15 % of wild-type when the sequences between 3-19 (deletion 1), 117-199 (4) and 246-338 (6) were missing. Similar results were obtained with the pgLRS (-198) CAT plasmid except that in this case the ability of EBNA2 mutants lacking the arginine-glycinerich sequence between residues 336-389 (deletion 7) or the adjacent 387-437 sequence (8) to transactivate the reporter plasmid was reduced to 20 % of wild-type. This clearly suggests that this part of EBNA2 is directly or indirectly involved in the activation of the promoter through sequences in the -198/+40 LRS region, but that the effect can be compensated for by elements further upstream in LRS.
We next investigated the ability of the EBNA2 mutants to activate transcriptional elements present in the proximal part of the EBNA Cp regulatory region by cotransfection assays in DG75 cells. Two different Cp-CAT constructs were used: pCp(-1024)CAT, which includes all upstream regulatory elements except oriP; and pCp(-248)CAT in which the EBNA2-responsive part with the RPB-Jt¢ site has been deleted. The results obtained with pCp(-1024)CAT showed that the Cterminal part of EBNA2 is mainly responsible for the ability to activate the Cp regulatory elements, since deletion of amino acids 247-337 (deletion 6), 337-388 (7) and 437-476 (9) substantially reduced or abrogated transactivation (Fig. 3 c) . The pCp(-248)CAT reporter plasmid was not activated by wild-type EBNA2 but was to a small extent (about twofold) by mutants with deletions in the proline-rich part (residues 57-116; deletion 3).
When the patterns of promoter transactivation by EBNA2 mutants were compared it became obvious that different protein domains participated in the activation of the LMP1 and Cp promoters (Fig. 3 d) . Four EBNA2 domains, amino acids 4-18 (deletion 1), 118-198 (4), 247-337 (6) and 437-476 (9) clearly contributed to the transactivation of the LMP1 promoter. In contrast, two of the domains required for LMP1 promoter activation, residues 4-18 (deletion 1) and 118-198 (4), were not important for the transactivation of Cp. Furthermore, amino acids 337-388 (deletion 7) and to some extent 388-436 (8) were required for efficient EBNA2-dependent transactivation of Cp but not for the LMP1 promoter. It is also interesting to note that EBNA2 caused only a fourfold activation of the Cp promoter as compared to the 27-fold activation of the LMP1 promoter under similar conditions. Our results confirm the previous findings by and and extend them by the identification of two additional regions (amino acids 4-18 and 118 198 ) as critical for EBNA2 responsiveness of the LMP1 promoter. However, the proline-rich region at residues 19-115 was not important for the EBNA2 induction in our experiments. Yalamanchili et al. (1994) analysed the contribution of two amino acids in strain W91 EBNA2A (corresponding to residues 323 and 324 in strain B95-8 EBNA2A) to the transactivation of the LMP1 and Cp promoters by site-directed mutagenesis. These amino acids have been shown to be critical for the interaction between EBNA2 and RBP-J~c. Mutation of the two amino acids totally abrogated EBNA2 induction of Cp while the LMP 1 promoter was still significantly activated by EBNA2. Deletion of the corresponding region (amino acids 247-337; deletion 6 in our series of EBNA2 mutants) resulted in a loss of ability to activate both LRS and Cp, which thus cannot solely be explained by an inability of EBNA2 to interact with RBP-J~c. This conclusion is strengthened by our observation that the same deletion totally abolished transactivation of the pgLRS (-198) CAT construct which does not contain a RBP-JK-binding site. The region of EBNA2 defined by the deletion of amino acids 247-337 must therefore also be involved in other types of interactions. It has been suggested by Tsui & Schubach (1994) that EBNA2 domains corresponding to residues 122-232 and 232-344 participate in the oligomerization of EBNA2 in vitro as well as in vivo. These domains overlap with two of the deletions in our series of EBNA2 mutants (118 198, deletion 4; 247-337, deletion 6 ) that both seriously diminish the ability of EBNA2 to transactivate the LMP1 promoter. Since both domains of the EBNA2 protein seem to be required for oligomerization, this might be an obligatory step in the EBNA2-induced activation of the LMP1 promoter and suggests a possible second function for the 247-337 region apart from interacting with RBP-JK. Interestingly, only one of the deletions (deletion 6, 247-337) reduced the activation of Cp, indicating that oligomerization might not be necessary in this case.
We have previously reported on the existence of a possible relationship between the EBNA2 effect on LMP1 in B cells and the cAMP signal transduction pathway (F~thraeus et al., 1994) . In the present context it is interesting to note that a fragment spanning positions 324436 of the EBNA2A sequence fused to the glutathione S-transferase (GST) protein specifically interacted with a component in DG75 nuclear extracts that had protein phosphatase 1 or 2A (PP1 or PP2A)-like properties. Furthermore, PP1/PP2A-like activity in the extracts was specifically inhibited by the same GST-EBNA2 fusion product. The effects were not seen with a GST fusion protein that included amino acids 383-487 of EBNA2A. The results would then suggest that the 324~383 region of EBNA2, which is contained within the region deleted in deletion 6 and 7, might mediate the inhibition of dephosphorylation of a transcription factor that binds to the CRE motif at position -44 to -36 in Relative Cp inducibility LRS; it would thus be part of a regulatory loop that controls the activity of the LMP1 promoter.
Tong et al. (1994) All the domains of EBNA2 defined here as important for transactivation contain conserved motifs between B95-8 (type 1 strain), AG876 (type 2 strain) and herpesvirus papio EBNA2 (Ling et al., 1993b) . Corresponding regions of the protein have been shown to be necessary for growth transformation of B lymphocytes , with the exception of that defined by the N-terminal deletion of amino acids 4-18 in our study (deletion 1), which was not investigated. It is well established that a transcription factor can participate in different types of interactions such as DNA binding, formation of homo-or heterodimers or multimeric complexes, protein phosphorylation or dephosphorylation, etc. Such reactions are often rate-limiting steps in regulatory pathways leading to transcriptional activation. From our results and those of others it seems most probable that different EBNA2-dependent promoters can be activated by different mechanisms and at least some of them via more than one of several accessible pathways.
